Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705509 · ClinicalTrials.gov registry record · NA
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
A NA study, sponsored by Cardiovascular Institute of the South Clinical Research Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01705509: Clinical Trial NA study, sponsored by Cardiovascular Institute of the South Clinical Research Corporation.
NCT01705509 is a NA study that was terminated before completion, run by Cardiovascular Institute of the South Clinical Research Corporation. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01705509, a NA study, was terminated before completion, sponsored by Cardiovascular Institute of the South Clinical Research Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a proof of concept trial using ranolazine, a medication, in patients with known Coronary Artery Disease and reduced left ventricular function, EF \< 40%. We propose that ranolazine therapy will result in demonstrative improvements in cardiac function that can be objectively assessed using the parameters measured with CPET. We propose that demonstrative improvement in CPET parameters on ranolazine will translate into improved patient outcomes for this patient population.
Primary Outcome
CPET parameters assessed will include the peak VO2: measures the peak transport of O2 to the tissues when O2 extraction from the blood is maximal; 2) the anaerobic threshold (AT): measures the sustainable work capacity in units of VO2; 3) the O2-pulse measurements at the AT and peak VO2: estimate stroke volume at those levels of exercise; and 4) the relationship of O2 uptake to work rate (ΔVO2/ΔWR): provides information on the ability of the cardiac output to increase.
Interventions
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-03-31 |
| Phase | NA |
Why NCT01705509 stopped before completion
NCT01705509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Ranolazine is the first listed.
NCT01705509 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01705509 about?
NCT01705509 is a clinical study titled "The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)". This is a proof of concept trial using ranolazine, a medication, in patients with known Coronary Artery Disease and reduced left ventricular function, EF \< 40%. We propose that ranolazine therapy will result in demonstrative improvements in cardiac function that can be objectively assessed using th...
What is the current status of trial NCT01705509?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2012-09. Estimated completion is 2017-03-31.
What interventions are being tested in trial NCT01705509?
The interventions under investigation include: Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01705509?
This trial is sponsored by Cardiovascular Institute of the South Clinical Research Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01705509's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia